Standard

Mouse-adapted influenza B virus for in vitro and in vivo assessment of therapeutic and preventive efficacy of antiviral drugs. / Prokopyeva, E. A.; Kurskaya, O. G.; Solomatina, M. V. et al.

In: Jurnal Infektologii, Vol. 11, No. 4, 01.04.2019, p. 53-64.

Research output: Contribution to journal › Article › peer-review

Harvard

Prokopyeva, EA, Kurskaya, OG, Solomatina, MV, Sobolev, I, Murashkina, T, Derko, A, Korchagina, KV, Yunusova, AY, Alekseev, AY, Shestopalov, A, Sysolyatin, SV, Vorozhtsov, AB, Vaizova, O, Sherstoboev, EY, Sharshov, K & Dygai, A 2019, 'Mouse-adapted influenza B virus for in vitro and in vivo assessment of therapeutic and preventive efficacy of antiviral drugs', Jurnal Infektologii, vol. 11, no. 4, pp. 53-64. https://doi.org/10.22625/2072-6732-2019-11-4-53-64

APA

Prokopyeva, E. A., Kurskaya, O. G., Solomatina, M. V., Sobolev, I., Murashkina, T., Derko, A., Korchagina, K. V., Yunusova, A. Y., Alekseev, A. Y., Shestopalov, A., Sysolyatin, S. V., Vorozhtsov, A. B., Vaizova, O., Sherstoboev, E. Y., Sharshov, K., & Dygai, A. (2019). Mouse-adapted influenza B virus for in vitro and in vivo assessment of therapeutic and preventive efficacy of antiviral drugs. Jurnal Infektologii, 11(4), 53-64. https://doi.org/10.22625/2072-6732-2019-11-4-53-64

Vancouver

Prokopyeva EA, Kurskaya OG, Solomatina MV, Sobolev I, Murashkina T, Derko A et al. Mouse-adapted influenza B virus for in vitro and in vivo assessment of therapeutic and preventive efficacy of antiviral drugs. Jurnal Infektologii. 2019 Apr 1;11(4):53-64. doi: 10.22625/2072-6732-2019-11-4-53-64

Author

Prokopyeva, E. A. ; Kurskaya, O. G. ; Solomatina, M. V. et al. / Mouse-adapted influenza B virus for in vitro and in vivo assessment of therapeutic and preventive efficacy of antiviral drugs. In: Jurnal Infektologii. 2019 ; Vol. 11, No. 4. pp. 53-64.

BibTeX

@article{c274f3657f6c47d9826f314f4cda70d7,
title = "Mouse-adapted influenza B virus for in vitro and in vivo assessment of therapeutic and preventive efficacy of antiviral drugs",
abstract = "Objective: to develop a new antigenic relevance influenza B virus suitable for modeling influenza infection in mice to assess of in vivo and in vitro therapeutic and preventive efficacy of antiviral drugs. Materials and methods: was carried out an adaptation of influenza B virus in BALB/c mice. Was performed comparative assessment of in vivo and in vitro pathogenicity of the parental virus and adapted influenza B virus. Was assessed inhibition of neuraminidase with antiviral drugs (oseltamivir ethoxyacrylate and Tamiflu) in relation to the adapted influenza B virus. Results: adapted influenza B virus (B/ Novosibirsk/40/2017-MA strain) models non-lethal influenza infection with pronounced clinical signs of the disease in experimental animals. Were described the destructive changes in lungs and brain that increases during infection. Analysis of internal organs (lungs, brain, liver, heart, kidneys, spleen) were revealed viral load only in the lungs. Were evaluated in vivo and in vitro efficacy of antiviral drugs (oseltamivir ethoxysuccinate and Tamiflu{\textregistered}) on the model of influenza infection. Were proved the high efficiency of the innovative drug – oseltamivir ethoxysuccinate. Conclusion: the antigen-relevant adapted influenza B virus (В/Novosibirsk/40/2017-MA strain) can be used to assess the drug effectiveness against influenza, as well as an additional tool for predicting the effectiveness of the vaccine against drifting strains.",
keywords = "Adapted influenza virus B, Antiviral drug (oseltamivir ethoxysuccinate, Influenza model, Tamiflu{\textregistered})",
author = "Prokopyeva, {E. A.} and Kurskaya, {O. G.} and Solomatina, {M. V.} and I. Sobolev and T. Murashkina and A. Derko and Korchagina, {K. V.} and Yunusova, {A. Y.} and Alekseev, {A. Y.} and A. Shestopalov and Sysolyatin, {S. V.} and Vorozhtsov, {A. B.} and O. Vaizova and Sherstoboev, {E. Y.} and K. Sharshov and A. Dygai",
note = "Прокопьева Е.А., Курская О.Г., Соломатина М.В., Соболев И.А., Мурашкина Т.А., Дёрко А.А., Корчагина К.В., Юнусова А.Ю., Алексеев А.Ю., Шестопалов А.М., Сысолятин С.В., Ворожцов А.Б., Ваизова О.Е., Шерстобоев Е.Ю., Шаршов К.А., Дыгай А.М. Вариант вируса гриппа в, адаптированный к мышам, для изучения лечебной и профилактической эффективности противовирусных препаратов in vitro и in vivo // Журнал инфектологии. - 2019. - Т. 11. - № 4. С. 53-64",
year = "2019",
month = apr,
day = "1",
doi = "10.22625/2072-6732-2019-11-4-53-64",
language = "English",
volume = "11",
pages = "53--64",
journal = "Jurnal Infektologii",
issn = "2072-6732",
publisher = "Interregional public organization Association of infectious disease specialists of Saint-Petersburg and Leningrad region (IPO AIDSSPbR)",
number = "4",

}

RIS

TY - JOUR

T1 - Mouse-adapted influenza B virus for in vitro and in vivo assessment of therapeutic and preventive efficacy of antiviral drugs

AU - Prokopyeva, E. A.

AU - Kurskaya, O. G.

AU - Solomatina, M. V.

AU - Sobolev, I.

AU - Murashkina, T.

AU - Derko, A.

AU - Korchagina, K. V.

AU - Yunusova, A. Y.

AU - Alekseev, A. Y.

AU - Shestopalov, A.

AU - Sysolyatin, S. V.

AU - Vorozhtsov, A. B.

AU - Vaizova, O.

AU - Sherstoboev, E. Y.

AU - Sharshov, K.

AU - Dygai, A.

N1 - Прокопьева Е.А., Курская О.Г., Соломатина М.В., Соболев И.А., Мурашкина Т.А., Дёрко А.А., Корчагина К.В., Юнусова А.Ю., Алексеев А.Ю., Шестопалов А.М., Сысолятин С.В., Ворожцов А.Б., Ваизова О.Е., Шерстобоев Е.Ю., Шаршов К.А., Дыгай А.М. Вариант вируса гриппа в, адаптированный к мышам, для изучения лечебной и профилактической эффективности противовирусных препаратов in vitro и in vivo // Журнал инфектологии. - 2019. - Т. 11. - № 4. С. 53-64

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Objective: to develop a new antigenic relevance influenza B virus suitable for modeling influenza infection in mice to assess of in vivo and in vitro therapeutic and preventive efficacy of antiviral drugs. Materials and methods: was carried out an adaptation of influenza B virus in BALB/c mice. Was performed comparative assessment of in vivo and in vitro pathogenicity of the parental virus and adapted influenza B virus. Was assessed inhibition of neuraminidase with antiviral drugs (oseltamivir ethoxyacrylate and Tamiflu) in relation to the adapted influenza B virus. Results: adapted influenza B virus (B/ Novosibirsk/40/2017-MA strain) models non-lethal influenza infection with pronounced clinical signs of the disease in experimental animals. Were described the destructive changes in lungs and brain that increases during infection. Analysis of internal organs (lungs, brain, liver, heart, kidneys, spleen) were revealed viral load only in the lungs. Were evaluated in vivo and in vitro efficacy of antiviral drugs (oseltamivir ethoxysuccinate and Tamiflu®) on the model of influenza infection. Were proved the high efficiency of the innovative drug – oseltamivir ethoxysuccinate. Conclusion: the antigen-relevant adapted influenza B virus (В/Novosibirsk/40/2017-MA strain) can be used to assess the drug effectiveness against influenza, as well as an additional tool for predicting the effectiveness of the vaccine against drifting strains.

AB - Objective: to develop a new antigenic relevance influenza B virus suitable for modeling influenza infection in mice to assess of in vivo and in vitro therapeutic and preventive efficacy of antiviral drugs. Materials and methods: was carried out an adaptation of influenza B virus in BALB/c mice. Was performed comparative assessment of in vivo and in vitro pathogenicity of the parental virus and adapted influenza B virus. Was assessed inhibition of neuraminidase with antiviral drugs (oseltamivir ethoxyacrylate and Tamiflu) in relation to the adapted influenza B virus. Results: adapted influenza B virus (B/ Novosibirsk/40/2017-MA strain) models non-lethal influenza infection with pronounced clinical signs of the disease in experimental animals. Were described the destructive changes in lungs and brain that increases during infection. Analysis of internal organs (lungs, brain, liver, heart, kidneys, spleen) were revealed viral load only in the lungs. Were evaluated in vivo and in vitro efficacy of antiviral drugs (oseltamivir ethoxysuccinate and Tamiflu®) on the model of influenza infection. Were proved the high efficiency of the innovative drug – oseltamivir ethoxysuccinate. Conclusion: the antigen-relevant adapted influenza B virus (В/Novosibirsk/40/2017-MA strain) can be used to assess the drug effectiveness against influenza, as well as an additional tool for predicting the effectiveness of the vaccine against drifting strains.

KW - Adapted influenza virus B

KW - Antiviral drug (oseltamivir ethoxysuccinate

KW - Influenza model

KW - Tamiflu®)

UR - http://www.scopus.com/inward/record.url?scp=85084032063&partnerID=8YFLogxK

U2 - 10.22625/2072-6732-2019-11-4-53-64

DO - 10.22625/2072-6732-2019-11-4-53-64

M3 - Article

AN - SCOPUS:85084032063

VL - 11

SP - 53

EP - 64

JO - Jurnal Infektologii

JF - Jurnal Infektologii

SN - 2072-6732

IS - 4

ER -

ID: 24228203